Francis M. Sirotnak
Program in Molecular Pharmacology and Experimental Therapeutics
Memorial Sloan-Kettering Cancer Center
New York
New York
USA
Name/email consistency: high
- Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Sirotnak, F.M., She, Y., Lee, F., Chen, J., Scher, H.I. Clin. Cancer Res. (2002)
- Markedly decreased binding of vincristine to tubulin in vinca alkaloid-resistant Chinese hamster cells is associated with selective overexpression of alpha and beta tubulin isoforms. Sirotnak, F.M., Danenberg, K.D., Chen, J., Fritz, F., Danenberg, P.V. Biochem. Biophys. Res. Commun. (2000)
- A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Sirotnak, F.M., Sepp-Lorenzino, L., Kohl, N.E., Rosen, N., Scher, H.I. Cancer Chemother. Pharmacol. (2000)
- Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Sirotnak, F.M., Wendel, H.G., Bornmann, W.G., Tong, W.P., Miller, V.A., Scher, H.I., Kris, M.G. Clin. Cancer Res. (2000)
- Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Sirotnak, F.M., Zakowski, M.F., Miller, V.A., Scher, H.I., Kris, M.G. Clin. Cancer Res. (2000)
- Carrier-mediated membrane transport of folates in mammalian cells. Sirotnak, F.M., Tolner, B. Annu. Rev. Nutr. (1999)
